Sartorius and Waters Expand Analytics Collaboration

Waters Corporation and Sartorius announced a new analytics collaboration on June 5, 2023. This agreement, which expands on their existing agreement that focused on upstream bioprocessing analytics, aims to develop integrated analytical solutions for downstream biomanufacturing.

According to a company press release, the collaboration will use Waters’ liquid chromatography and Sartorius’ multi-column chromatography platforms to develop a more comprehensive analytical data solution. This system will be used for downstream batch and continuous manufacturing with the goal of improving yields, reducing waste, and cutting costs.

“From the beginning of our collaboration with Sartorius, we’ve strived to give bioprocess engineers faster and more direct access to critical quality attribute information about their drug products in the name of improving production yields and getting drugs to patients faster,” said Jon Pratt, senior vice-president, Waters Division, in the release. “Based on the positive response of customers to our collaborative efforts with upstream bioprocessing analytics, we see tremendous benefit to combining [our platforms] to bring timely point-of-decision analytics to downstream biomanufacturing for monoclonal antibodies, recombinant proteins, vaccines and AAV gene therapies.”

“Now that intensified, continuous manufacturing of biologics is becoming a reality, there is a greater need for real-time analytical measurement,” said René Fáber, head of Bioprocess Solutions Division, Sartorius, in the release. “The value of combining technologies from Sartorius and Waters lies in bringing fundamentally important analytics to the point where it is needed and giving bioprocess engineers a more complete understanding of their downstream manufacturing processing and its effects on drug product quality. We believe this can have significant impacts on drug production costs by helping to increase yields and reduce waste.”

Source: Sartorius